newsfilter
← Latest News
Business Wire·

Buxton Helmsley Issues Letter to Assertio Stockholders Disclosing Inversion to Short Position Following Board Refusal to Address Product-Related Fraud

Well-Documented Evident Product-Related Fraud Related to the Acquisition of Spectrum Pharmaceuticals' Rolvedon Biologic Illuminates the Basis for Assertio's Massive Write-Down of Spectrum Immediately After